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Innovations in engineering applied to healthcare make a significant difference to people’s 
lives. Market growth is guaranteed by demographics. Regulation and requirements for Good 
Manufacturing Practice – extreme levels of repeatability and reliability – demand high 
precision process and measurement solutions. Emerging technologies using living biological 
materials add complexity. This paper presents the results of work demonstrating the precision 
automated manufacture of living materials, particularly the expansion of populations of 
human stem cells for therapeutic use as regenerative medicines. The paper also describes 
quality engineering techniques for precision process design and improvement and identifies 
the requirements for manufacturing technology and measurement systems evolution for such 
therapies. 
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1. Introduction 
 
Regenerative medicine (RM) is widely seen as the next major innovation in healthcare. The 
ability to repair and replace damaged cells and tissue, using emerging technologies such as 
stem cells, offers the potential of lifetime cures for unmet medical needs, including 
conditions such as Alzheimer's, heart failure, blindness and joint degeneration. The key to 
RM is that the product is the process. Creation of novel manufacturing technologies and skills 
gives an opportunity to secure a long term industrial presence that captures the entire value 
system. 
Regenerative medicines replace or regenerate human cells, tissues or organs to restore or 
establish normal function [1]. They have the potential to revolutionise methods of health care 
treatment and improve the quality of life for many. RM is now established as an important 
branch of medicine – the industry is starting to enjoy commercial success with annual sales of 
over $1billion; a large number of products are in clinical development having real long term 
potential for public health benefit. The market shift to commercial products based on stem 
cells is likely to mature in the next 5 to 10 years, with a series of therapies for cardiovascular 
conditions, cancer, arthritis, and trauma in the pipeline. RM is an emerging industry with a 
unique opportunity to contribute to health and wealth. It is a high value, science based 
manufacturing industry whose products tackle the consequences of aging and chronic disease. 
The industry, however, currently still faces a number of critical challenges including 
problems of commercial viability and company growth, limited revenue, and lack of 
investment. The key issue determining poor sales is the lack of clinical uptake of cell therapy 
products; this is mainly related to difficulties in establishing clinical utility and cost 
effectiveness. Creating an appropriate evidence base is the key to addressing this deficit. 
Businesses therefore have a primary focus on successfully reaching ‘first in man’ clinical 
2 
 
targets; this must be followed by the ‘one to many’ translation process, such that effective 
therapies can be produced at scale, and at a price society can afford. Although effective 
therapies that demonstrate positive health outcomes are being developed, the key barriers 
facing firms relate to important aspects of the translation process. These include establishing 
closer collaboration with clinical end users, greater regulatory clarity, clearer reimbursement 
policies based on economic evidence of the cost benefit of product solutions in application in 
the market place, rapid post approval adoption, and the need to develop enabling technologies 
that lower manufacturing costs [2]. Recent regulatory decisions also demand more clarity in 
the criteria that define product performance. 
 
(a) A glimpse of the clinical opportunity 
 
There is a continuous increase in demand for novel treatment strategies to treat tissue or 
organ damage, due to the rise in the mean life expectancy coupled with a severe shortage of 
donor organs and the limitations of conventional treatment regimes. Allogeneic transplants, 
autografts, xenografts and medical devices all have their inherent shortcomings, replacing the 
diseased tissue or organ imperfectly, and with issues of availability in the case of transplants, 
as well as frequently requiring immunosuppressive treatment. Researchers globally regard 
stem cell therapies as a treatment option with the potential to alter the face of contemporary 
medicine, and ultimately give a new and effective dimension to medical therapeutics. Recent 
work in RM, see the review [3], has provided the proof of principle for cell-based 
replacement for a number of structures ranging from skin, musculoskeletal and neuronal 
tissue to osteochondral grafts and complex organs such as the kidney which may supplant 
more conventional therapeutics to revolutionize current medical practice. 
 
2. Precision in a Regulated Market 
 
Healthcare is one of the most attractive of the markets for high added value manufactured 
goods, it does however have characteristics that differentiate it from more conventional 
markets, see [4] and [5]. Particularly important is the influence of industry specific regulation 
on the new product introduction process, focussed on ensuring safety and effectiveness of 
new products (for instance the requirements for clinical trials) and on the manufacturing 
process itself, with the requirement for GMP and cGMP, (current) Good Manufacturing 
Practice [6]. Overall these regulations require tight definition and control of product and 
process from a very early stage; consequently well established, if conservative, 
manufacturing methods have been much preferred. Many product failures during 
development are attributable to the transition from laboratory prototype to industrialised 
product, leading to product safety problems and a lack of effectiveness, the main causes of 
failure in the clinic. The lack of integration of product and process design frequently leads to 
late stage failures and extended product development project timescales because of 
significant requirements for rework. The business risks of operational quality failures in 
pharmaceutical and medical device technology supply cannot be underestimated as they can 
include product recall costs, multi-million dollar fines, litigation, share price decline and 
compulsory plant closures. 
Perhaps the most complex products to manufacture in this domain are those that represent 
the convergence of both medical device and pharmaceutical products. They add an extra layer 
of complexity to this already challenging process. RM/tissue engineered products represent 
characteristic current and emerging generations of such products. Some of these products will 
also routinely include human living material and systems adding biological complexity 
(variation and heterogeneity) to the relentless increase in the precision [7] demanded from 
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manufacturing processes. These products are likely to also require a transition in their 
manufacturing philosophy from biology carried out at the laboratory bench by experts to an 
engineered production method that frequently automates a process which initially shows 
many of the features of a craft [8]. 
As we have described above, only over very recent years has stem cell culture begun to be 
approached from a cost-effective manufacturing perspective – key to making the economic 
and business case for these potentially transformative new therapies. Critical aspects of the 
manufacturing approach are that the production system takes account of the number of 
products to be made and that machines are used as an alternative to people carrying out the 
process – both first identified by Charles Babbage in his discussion distinguishing between 
“making” and “manufacturing” in 1832 [9]. We have also learned through the work of the 
late Ramchandran Jaikumar in 1988, published posthumously by his colleague Robert Bohn 
[10], studying the evolution of manufacturing over 500 years that epochal change in 
manufacturing is achieved via breakthroughs in process control – the “art to [manufacturing] 
science” transition that increases our knowledge of the process and allows us to more 
completely specify manufacturing procedures. This is exemplified by the statistical quality 
control and process design techniques pioneered by Shewart in the US (at AT&T) and Fisher 
in the UK. Deming applied these widely to great effect in both manufacturing and supply in 
the US during the second world war and with Japanese industry in their post war rebuilding 
[11], this approach ultimately leading to “six sigma” philosophies emphasising the control of 
variation and quality by design. The manufacturing community is also aware of the inevitable 
increase of process precision achieved [7] – roughly an order of magnitude every decade or 
so – driven by progressive and reinforcing increases in the precision of the manufacturing 
process and the measurement system applied. The manufacturing community has learnt and 
applied these trends and principles in mechanical engineering domains including the small-
arms and the automotive industry, in electrical and electronic engineering domains including 
semi-conductors and complex assembly, and in the chemical engineering domains of the bio-
pharmaceuticals industry including the manufacture of antibodies. Each of these principles is 
being applied and the trends being perceived as a new manufacturing community brings stem 
cell bio-manufacturing from the laboratory of the expert biologist to the GMP facility of the 
manufacturer under the watchful eye of the regulator. 
Process excellence and/or lean sigma approaches centre on the use of a portfolio of 
process centred tools and techniques, emphasising the use of data driven and statistical 
thinking including statistically designed experiments, that allow the creation of highly 
capable manufacturing processes with controlled and understood variation (Cp, essentially 
the “centred” ratio of specification to process output, and Cpk, the “un-centred” ratio, to 
ultimately parts per million (ppm) failure rates), with minimum waste and that have as their 
ultimate goal “quality by design” or sometimes “robust design”. Rather than post-process 
inspection, the quality of the end product is then assured by the quality of each individual 
process step and the robustness of the final quality to the variation of the process steps, where 
each process step has been designed to be capable. Such consistent production and the ability 
to execute the same process in the same way, is also at the core of regulated, GMP, 
manufacturing. Implementing later changes to the process is often problematic; the process 
must create the same product that successfully went through clinical trials and showed safety 
and efficacy. It is also usually required to make the ultimate product by the same processes 
that were used to make the large scale (Phase III) clinical trials batches, in part because it is 
very difficult with biological material to fully characterise the finished product and 
demonstrate equivalence with material made by another technique. Process control and more 
particularly early capable and scalable process design are consequently of great importance, 
particularly for products or processes that are novel [12]. It is this requirement for 
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consistency together with increasing cost pressures within healthcare that are driving the 
increasing use of automation in these regulated industries. 
These trends are echoed by the emphasis of the US regulator, the Food and Drug 
Administration (FDA), on Process Analytical Technology, manufacturing science and quality 
by design. The FDA argue that “a profound understanding of the interrelationship between 
product and process quality” is required before real time release, i.e. product release with no 
end of line testing, will be possible. To the FDA, “profound understanding” means: all 
critical sources of variation are identified and explained; variability is managed by the 
process; and product quality attributes can be accurately and reliably predicted. Profound 
understanding may give “regulatory relief” in submissions. To meet these challenges 
companies are adopting six sigma style programmes to develop a detailed understanding of 
their processes while improving their profit margins under increasing pressure on unit cost. 
The application and awareness of these techniques is happening somewhat later in these 
highly regulated industries than it did for the conventional manufacturing industries. 
It is important to recognise that such regulated manufacturing, in summary, requires: 
• a consistent and well documented approach to product and process design with 
effective change control and risk management; 
• a detailed product definition and specification (with limits) traceable to clinical need;  
• a capable (repeatable), optimised (frequently automated) process and a processing 
machine, with a process window for improvements; 
• a capable measurement system, traceable to absolute standards; and 
• statistical and first (physical) principle process models relating key input and output 
variables. 
There is also a requirement for a more integrated approach to product and process design, 
particularly to the development, transfer and validation of manufacturing processes. 
 
3. The manufacturing challenge 
 
RM and tissue engineering are maturing through a translational phase from lab-based 
experimental disciplines to a nascent industry. Projected clinical demand indicates that within 
the next decade this industry will need to responsively and economically provide a diverse 
range of RM products, many of which will incorporate living cells, to a large market. This 
transformation is driving a need for novel, robust manufacturing systems for cell-based 
products that can meet the stringent regulatory requirements imposed on medical product 
manufacture. 
The requirement to manufacture living products for RM applications poses significant new 
challenges. These challenges revolve around the complexity of the living product and its 
sensitivity to environmental conditions. A living cell is in a constant state of change in 
response to its environment, and therefore maintaining product quality requires precise 
process control. Cell products always incorporate some degree of heterogeneity due to 
different micro-environments in the manufacturing process. Furthermore, the complexity of a 
living cell defies comprehensive definition; measurement of product quality is usually based 
on average population values of surrogate markers (i.e. critical gene or protein expression) 
that are at best indicative of critical product attributes (therapeutic efficacy, safety). The 
inherent pluripotency of stem cells exacerbates the challenge. 
Many of the solutions and technologies that have been developed for conventional 
biologics manufacture cannot be applied to cell therapies. Large volume suspension 
bioreactors that are well characterised for cell line production are not readily adapted to the 
culture of adherent cell types such as those required for most cellular products. As the cells 
themselves, rather than an excreted culture by-product, are the product, conventional 
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downstream purification also has limited use. The greater sensitivity of therapeutic cells and 
the difficulty of product measurement enforce greater reliance on process understanding and 
control to guarantee product safety and efficacy. 
Achieving a controlled and characterised manufacturing process for cell based therapies 
requires the development of new technologies, tools and techniques, as well as the transfer of 
manufacturing experience from diverse older industries. In addition to the technical 
challenges outlined, manufacturing equipment, processes and facilities must be compliant 
with good manufacturing practice (GMP), the stringent regulatory framework controlling 
therapeutic product manufacture. 
Variation in the manufactured RM product can come from two sources: process input 
material and process conditions. If identical batches of input material are subject to identical 
processing conditions they will produce identical product. Relative to conventional 
pharmaceutical or biologic production, both input material variation and process condition 
variation have been poorly controlled in cell therapy manufacture. Although the complexities 
are specific to the RM industry, generic methods from other industries, in particular process 
automation and systematic process improvement methods, are instructive when approaching 
this challenge. 
Process automation has been a key mechanism for achieving controlled and standardised 
processes in many manufacturing industries. Automation also enables scale-out, replication 
of the unit process of production, with predictable process variation and therefore predictable 
process costs, in marked contrast to scale-up, an increasing of the physical volume, of manual 
laboratory operator processing. Systematic process improvement methods, such as the ‘six 
sigma’ approach, have been developed in electronics and automotive manufacturing in order 
to understand and control sources of process variation and thereby reduce the rate of 
defective products. 
 
(a) Automated manufacture 
 
The first step undertaken in the work reported here was therefore to remove manual 
operator processing from the manufacturing process of important therapeutic cell types and 
bring the processes under machine control. The CompacT SelecT robotic flask handling 
platform was developed as the current best candidate production technology to remove 
operator variation from the manufacture process. The platform consists of a robotic arm in a 
clean processing environment adjacent to an incubator. The system can carry out most cell 
processing activities on bar code tracked adherent cell culture flasks with relatively few 
deviations from conventional manual processing protocols that would be developed in the 
early stages of a product’s evolution. This similarity to manual flask processing increases 
confidence that cell product quality will not be affected and makes process automation of 
flask based processes that are advanced in clinical development (where important historical 
process data exists) feasible. The commercial availability of the machine offers a significant 
advantage over prior non-commercialised or non-scalable bespoke robotic developments [13, 
14]. 
Key therapeutic cell types and associated commercial and academic partners (‘customers’ 
in a quality engineering sense) were selected to demonstrate the efficacy of automated cell 
production using the system. Successful automated production protocols were developed for 
human mesenchymal stem cells [15] and human embryonic stem cells [16] as these represent 
the cell stock source for a significant proportion of cell therapies under development. Further 
work with collaborators also developed automated production protocols for niche proprietary 
cell lines and products including neural stem cells [17] and smooth muscle progenitor cells. 
The cell types chosen were intentionally diverse. They covered examples of both autologous 
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and allogeneic applications, different handling requirements, and clinically acceptable 
production protocols. The automated production methods developed produced cells that met 
stringent quality specifications as identified by the customer and including cell proliferation, 
viability, genetic stability, biological markers and differentiation potency, see figure 1. 
 
Insert Figure 1 
 
In parallel with the program to automate key therapeutic cell types, it was important to 
demonstrate the improved reproducibility (using the accepted manufacturing metric of 
process capability) achieved through moving from manual to automated production. Figure 2 
shows the process capability of manual compared to automated production for an exemplar 
cell line manufacture process [18]. The process capability result is important for two main 
reasons. Firstly, it shows the automated process is in control, i.e. the variation is stable, and 
therefore enables the application of powerful statistical tools for process analysis. The manual 
equivalent usually shows increased variability due to variation between operators and 
operator induced artefacts, thereby masking true process related changes. Secondly it also 
provides a higher probability of batch failure allowing predictable production costs at scale 
when failures rates are currently high, costly and add risk. 
 
Insert Figure 2 
 
(b) Automated process improvement 
 
It has also been important to demonstrate the value of systematic process improvement 
methods as a tool for achieving controlled and optimised automated manufacturing processes. 
A ‘six sigma’ type approach was used, figure 3 and 4, as the context for applying statistically 
designed experiments (DOE) in automated mesenchymal stem cell production. The six sigma 
method helps maintain a systematic approach to process improvement. It involves the 
definition of critical to quality process attributes, measurement of the process performance, 
analysis of process performance, a data driven process improvement intervention and, finally, 
process monitoring to demonstrate maintained control post improvement. The power of DOE 
is to identify major process input effects on critical process outputs in the analysis phase with 
high experimental efficiency (i.e. results per experimental run). These multivariate 
experiments can also identify where input parameters are not independent (i.e. their 
individual effects are dependent on the levels of another parameter). This is critical data for 
achieving an optimal process as some input factors cannot be optimised independently. 
Figure 5 outlines the DOE analysis of critical process input variables for the automated 
production of mesenchymal stem cells [19]. Particularly important is the observed interaction 
between serum concentration and cell density. This shows the potential to reduce the use of 
undesirable production components such as serum with improved process understanding and 
proves the futility of attempting process analysis using one-factor-at-a-time experimental 
approaches. Recent work has applied response surface methods to optimising the culture of 
human embryonic stem cells (hESC) with a particular focus on controlling cost of goods [20]. 
 
 
Insert Figure 3 
Insert Figure 4 
Insert Figure 5 
 
(c) Achieving GMP standards of cell manufacture 
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As the automated process development work progressed, consideration was given to the 
challenge of a production system that could meet the regulatory requirements for clinical 
production. Regulatory authorities demand stringent validation of equipment and facilities 
used in the production of therapeutic products for human application. Therefore, the 
transition of facilities and automation from non-GMP applications to GMP-validated 
equipment requires careful consideration of the processing machine, as well as the 
surrounding laboratory environment. Furthermore, the segregation of individual cell types, 
whether cell lines or individual patient cells, is pivotal to maintaining the quality of cell- and 
tissue-based products. If cross-contamination were to occur between individual patient 
samples in an autologous therapy regime, there would be the potential risk of adverse 
reactions due to the transfer of patient disease from one to another, or even negative immune 
reactions due to the body recognising cells as non-self. However, in terms of manufacturing 
multiple autologous therapies concurrently, the cost of complete segregation of patients’ cells 
in dedicated incubators and biosafety cabinets may make the cost of otherwise valuable 
therapies prohibitive. 
From a regulatory perspective, full qualification of reagents and source materials is 
required, along with appropriate manufacturing controls to ensure consistency and product 
quality of each cell lot. Environmental monitoring is of the utmost importance, with air 
quality, water quality, laboratory design, cleaning and personnel training and compliance all 
critical to product safety. For example, FDA standards (Code of Federal Regulations, CFR 
21) classify a critical area, i.e. an area in which a product is exposed to environmental 
conditions during manipulations, as requiring a per-cubic-metre particle count of <3520 in a 
size range of 0.5 µm and larger. Furthermore, a quality control (QC) plan also needs to be put 
into place to ensure proper manufacturing oversight, as well as providing the following 
functions: examination of the various production components; review and approval of 
production procedures, testing procedures and acceptance criteria; assessment of each clinical 
batch based on a cumulative review of completed production records and other relevant 
information; and investigation and initiation of corrective actions if unexpected results or 
errors occur during production. This QC plan then acts to prevent, detect and correct any 
deficiencies that may produce poor quality or unsafe products, such as the transmission of 
adventitious infectious agents. Finally, it is important that the QC plan establishes internal 
audits at planned intervals, and takes into account relative risk factors, previous audit results 
and corrective actions, with the completion of an annual audit of the complete operation. 
 
(d) The way forward 
 
Once this has been addressed, the current biggest challenge for manufacturers of cell- and 
tissue-based therapies is in the development of representative potency assays to evaluate the 
final product. According to a recent FDA guidance document, potency assays must be 
specific, quantitative, meet pre-defined criteria, include appropriate standards and controls, be 
fully validated and measure both identity and strength of all active ingredients. Therefore, 
due to the inherent heterogeneity in the cells themselves, these requirements can only be met 
if the product is fully defined and manufactured to the same consistent standards. This 
consistency will rely on strong quality systems controlling both the product and the 
manufacturing process itself. One way to combat this problem is through the concept of 
quality by design (QbD). 
QbD focuses on building quality into the product through a thorough understanding of 
both the product and process, combined with a clear knowledge of manufacturing risks along 
with appropriate mitigation strategies. This system can aid manufacturers by reducing time to 
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approvals, but can also build significant cost into the manufacturing process through the 
volume of testing required throughout production. Therefore, the choice of quality system 
needs to be carefully selected to maximise quality and minimise cost. Once this quality 
system is in place, potency assays can be developed as in vitro surrogate assays for the 
eventual efficacy of the therapy in vivo. Since the manufacturing process is now controlled, 
any variations in results will be due to the potency of the cells themselves, whether it be their 
potential to form colonies, or their ability to secrete proteins in response to a specific stimuli. 
In addition to this, there needs to be a strong focus on real-time monitoring of product 
manufacture and non-destructive, and preferably non-invasive, testing methods that will 
avoid cell wastage through onerous quality testing regimes. By improving these techniques, 
the cost of cell- and tissue-based therapies should be reduced, as fewer cells will be needed to 
provide an effective treatment, as well as to provide the evidence to satisfy the regulator that 
the treatment will be safe and effective. 
 
4. Manufacturing (systems) issues that remain to be addressed 
 
As has been implied above, manufacturing approaches have now been applied to therapeutic 
stem cell culture, however there is still much to do. When systematically considering 
manufacturing issues it is helpful to structure the perspective using a hierarchical model of 
manufacturing. Key areas to be examined should include: manufacturing and supply; strategy 
and location; organisation, operations and people; design and operation; the production 
system; individual machines and processes; the unit process; quality engineering, metrology 
and measurement systems analysis including the anticipated rate of change of precision. 
Those within the field are currently attempting to identify and create platform technologies 
and approaches for each level of this hierarchy. 
Discussions with industrial collaborators highlight the following issues that need to be 
addressed with respect to the manufacturing of RM products. 
 
(a) Manufacturing and supply; Strategy and location; 
Organisation, operations and people 
 
The location of manufacturing and structure of the supply chain are strongly dependent on 
the product and its method of preservation. Allogeneic products can be made remotely from 
the patient, much as a conventional pharmaceutical is, however autologous products, 
dedicated to a single patient, are usually processed near to the patient perhaps within a 
hospital location or at a centralised location serving a number of clinical sites. The supply 
process has to fit with the processes available at the ultimate destination in the hospital – 
critically this depends on whether the product is shipped at room temperature, shipped at a 
cold chain temperature (4ºC) or cryopreserved – the latter requiring temporary storage in 
freezers and subsequent cell resuscitation before reaching a patient. Cell therapies are 
relatively fragile living materials and require careful management of transport and the supply 
chain – achieving a consistent and long as possible shelf life is critical to this, as is the design 
of transport packaging and preservation systems [21, 22]. 
Many companies begin to make their first experimental products within their own or 
academic laboratories. The key manufacturing strategy decision for any company considering 
launching an RM product is the “make or buy” decision of whether manufacturing of the 
product is outsourced from a contract manufacturing organisation at some time during the 
new product introduction process. The decision made is strongly dependent on the culture 
and experience of the company in the regulated manufacturing of these living products – such 
experience is rare, for example, even in large pharmaceutical companies. The decision is also 
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influenced by the high capital cost of the necessary facilities and the regulatory burden 
associated with their licensing and operation. Critically, unlike a conventional small molecule 
pharmaceutical, for RM products manufacturing defines a significant proportion of cost of 
goods supplied (COGS), this in turn defines profitability and commercial viability. Control of 
manufacturing is therefore considered very important by some RM companies; this 
importance is reinforced by the recognition that “the product is the process” and that business 
must have absolute confidence that its product is made consistently. It should also be 
recognised that, even if the process is automated, high added value manufacturing businesses 
provide significant numbers of jobs in their location. This in turn can lead to regional 
interventions to either secure manufacturing investments or to ensure expansion of facilities 
takes place on an existing site. The financial implications of this can significantly modify 
location and “make or buy” decisions. 
As our discussion had begun to emphasise, the manufacturing of cell therapies is complex 
requiring: the handling of living human materials where the product is the living material; the 
ability to process these materials in a way that satisfies a regulator including Good 
Manufacturing Practice [6] within a Quality System; and the ability to address COGs issues. 
These require the building of significant and often new capabilities within an organisation 
and its people. 
 
(b) Design and operation of facilities, the production system 
 
That the “product is the process” means that there are very significant couplings [23, 24] 
between the design of the product and the design of the process and production system. A 
critical variable still to be established for RM products is the allowable variation in the 
critical parameters required for product performance – key components of the specification of 
the product defining what has to be achieved by manufacturing. In industries with traditional 
manufacturing processes we have, over long experience, developed a good understanding of 
the variation that can be achieved by the process. We have not yet measured this for the 
processes required to make RM products – we cannot therefore guide those specifying the 
products on the variation manufacturing can achieve and in consequence determine realistic 
targets for allowable variation. 
Whether the product is designed to be used in an allogeneic or an autologous application 
has a particularly important effect on the design of the manufacturing facility. In the first case 
the process is able to build on conventional engineering approaches as exemplified by the 
factory, or in chemical engineering approaches as exemplified by the process plant. In the 
second case, however, any manufacturing approach has to be effective for a “batch of one”. 
Furthermore, cell based products usually require the pre-preparation of cell banks. Depending 
on the scale required, cell banks may need to be started from a number of cell sources, with 
each cell source being likely to have slightly different expansion and other characteristics. 
This highlights that there is actually a continuum of approaches spanning autologous and 
allogeneic and that the production system must suit the particular position on the continuum 
of the product that is being processed. 
Each process within an RM manufacturing facility will require to be carried out within a 
controlled environment, consequently the facility will have a high capital cost; the capital 
(and operating) cost for the facility usually being determined by its footprint. Production 
machines have correspondingly high costs because of the requirements for, for instance, 
aseptic processing within the machine’s own environment and high levels of cleanliness 
because many RM products cannot be terminally sterilized or irradiated subsequent to 
processing. Process automation is increasingly being applied in the production of RM 
products because the automation, by eliminating the variation due to operators, brings the 
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process under control. Process control techniques are also being explored and supplied for 
similar reasons and to reduce variation. Many solutions are as yet bespoke with only a few 
standard processing platforms emerging for key process steps – bespoke solutions are 
expensive. A key technological challenge is creating such process platforms and designing 
production systems capable of changing with innovations in the process platform. 
 
(c) Individual machines and processes; the unit process 
 
There are a number of unit processes for the production of cell therapies. Production 
begins with the isolation of the cell sources from a biopsy – this happening perhaps once for 
an allogeneic therapy but requiring to be carried out for each patient receiving an autologous 
product. Isolation is necessarily variable depending on source. Cells for therapeutic use are 
frequently enriched – increasing the proportion of cells with therapeutic value – by sorting or 
centrifugation for example. “Minimal manipulation” approaches may be required to comply 
with the regulatory pathway. Many cell therapy approaches require cell number expansion in 
culture to generate sufficient cells for therapeutic use – this has been discussed above in some 
depth – and may require a subsequent differentiation step to convert stem cells to the cell of 
therapeutic interest. Two dimensional adherent culture “on plastic” or a cell suspension 
equivalent may not be sufficient to achieve a particular cell type and three dimensional 
structure systems may be required that allow mechanical as well as biological inter-cellular 
signalling, see [25]. 
As has been indicated above, the process and more particularly the culture media used in 
the process can drive up COGS. Applying techniques for process optimisation and improving 
them to take account of the particular constraints of RM is particularly important to both 
define practically achievable process variation and to improve processes. A key application 
area is the design of media formulation. This is a particular target because of its impact on 
COGS. Media has many components, often whose presence is based on historical precedent, 
including many that are either naturally derived or their recombinant equivalents – there is a 
requirement to establish which of the many components are really necessary to achieve a 
successful culture to specification. 
In addition to being able to achieve the biological requirements of each process step, 
process and production system design also has to be engineered so that it can satisfy the 
constraints of GMP, in particular that it can be straight forwardly validated. Key engineering 
considerations in unit process and machine design have to address aseptic processing, 
particularly the control of viable particulates, the ability to straight forwardly clean the 
device, and the management of contamination and cross contamination between batches. The 
challenges here are exemplified by the standards required for human stem cell processing for 
therapeutic use – one colony forming unit (CFU) per cubic metre. While the non-viable 
particulates allowed are higher, the viable particulate requirement reflects the levels of 
environmental control conventionally required for semi-conductor processing. Many of these 
issues are addressed by the design of processing consumables – “plastic ware” – again 
however these add very significantly to COGS. 
 
(d) Quality engineering, characterisation, metrology and measurement systems analysis, 
the anticipated rate of change of precision 
 
The core approach of this paper has been to present a quality engineering approach to the 
manufacturing problem for cell culture – this now needs to be applied to other process steps. 
Characterisation – the equivalent of metrology – is discussed at length below, with examples 
given in the discussion of the exemplar automated cell culture processes above. The 
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requirements for the level of process precision will inevitably increase – as they have in most 
other manufacturing fields.  Regulatory concerns to more carefully define the products in use 
are likely to drive this in the short term. In essence, the regulator takes the view that if you 
can better measure a relevant parameter then you must. Together with this increase in level of 
precision, the number of product and process variables for which precision is required will 
also inevitably increase [26]. 
 
5. Alternative process platforms 
 
The evolution of manufacturing systems for therapeutic cell based products is being driven 
by investment directed at process scalability, reproducibility and manufacturing cost 
reduction. The methods to achieve these goals are not yet established due to limited process 
understanding and conflicting incentives. Manufacturing technology developers are searching 
for a process specification generic enough to satisfy an adequately large market to support a 
commercially viable platform; this is difficult given the diversity, and sensitivity to process, 
of the products. Conversely, product developers are inherently cautious regarding 
manufacturing process modifications and therefore search for a bespoke manufacturing 
capability fitting their development specification; they lack the sophisticated quality control 
measures to robustly assess the consequences of process change or the economic models to 
guide manufacturing technology decisions. These drivers can explain the three major 
directions of development for the manufacture of cell based therapies: the technology push to 
implement existing platforms from the biopharmaceutical or cell product industry (low risk 
for machine makers who lack a clear specification); scale-out of existing methods (low risk 
for therapy developers but limited in scale and control); and the development of niche 
bioreactors within cell product development companies (bespoke environments but with high 
development costs and limited technology leverage). These approaches all continue to evolve 
and can each cite examples of success, but rarely without compromise. In most cases, 
therefore, the process arising is rarely optimal. 
A serious constraint on developing manufacturing solutions is both the diversity and poor 
definition of manufacturing requirements. Although the products are classified by their 
cellular component, they are extremely divergent in other characteristics relevant to the 
manufacturing process. It is misleading to think of development of a single manufacturing 
technology for RM. For example, the range of production scale requirements is likely to span 
at least ~107 to 1017 cells/yr for differing therapeutic indications. In the former case, adherent 
scale-out of current methods may be economically possible and controllable. In the latter case 
large high-density systems will be required with associated high-technology monitoring and 
control. Cost build-up in manufacture is likely to vary between products, potentially changing 
the emphasis for systems between criteria such as media efficiency and processing footprint. 
The monitoring and feedback control requirements are likely to vary depending on 
regulation, control of input materials, and critical-to-quality cell characteristics. Cell niche 
design (or the process design space) in the manufacturing technology will vary depending on 
the environmental sensitivity of the cell type and the acceptable clinical specification. Almost 
all of these factors are currently speculative and largely empirical. In addition to these 
considerations, autologous therapies and allogeneic therapies will require differences in batch 
size, product separation and other manufacturing parameters. These issues apply to simple 
cell suspension therapies; 3D tissue engineered products will add further complexity. 
Despite these difficulties, there are significant continuing advances within the three areas 
of development. The most significant recent progress is the adaptation of human embryonic 
stem cells to grow in microcarrier or carrier-free suspension culture format [27, 28]. This is 
an adaptation to available technology from the existing bio-manufacturing industry and for 
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the first time provides a possible route to produce the cell numbers required for high dose, 
high patient number therapies. Such systems are generally considered the most economic and 
easily controllable production mode, if viable, and have excellent development of 
physicochemical monitoring and a heritage of regulated industrial use [29]. However, they 
require a significant change from development processes, predominantly designed on planar 
polystyrene growth surfaces. Many other therapeutic cell types or specific differentiation 
pathways are unlikely to tolerate this adaptation without losing clinically critical features. For 
these applications recent developments include multilayered culture systems aimed at 
increasing the efficiency and scalability of planar adherent manufacture. However, these have 
been only cautiously adopted due to insufficient scalability advantages and process control 
concerns relative to standard planar culture [30]. Further advances in the automation of 
standard planar culture methods has shown promise, and improved control, but is afflicted by 
high entry costs and limited scalability. These planar culture system developments have 
necessitated parallel development of new non-invasive analysis methods, such as image 
analysis or spectroscopy [31, 32]. Finally, systems have been designed for high density 
support of adherent cells, often by virtue of diffuse mass exchange via perfused fibres or 
suspended particles. However, the complexity and 3D nature of these systems adds challenge 
in process control, scalability and operational procedures such as cell recovery [33]. 
Manufacturing for cell based therapies has, as yet, an unclear future direction and the 
design of future manufacturing technology will only become more rational as our 
understanding of the constraints improves. It is likely to involve multiple strands of 
technology development, a key criterion for which will be reducing the cost of both 
developing and producing high quality product. For a significant period the industry will rely 
on point solutions for common process areas and adopting technology from related industries. 
However, as the understanding of manufacturing requirements increases we anticipate the 
emergence of increasingly standardised cell therapy manufacturing solutions. 
 
6. Characterisation (of product and process) 
– metrology of critical-to-quality characteristics 
 
Characterisation is fundamental to the demonstration of adherence to good manufacturing 
practice (GMP) and underpins efforts to obtain product regulatory approval. Specifically, 
there is a need to demonstrate safety, efficacy and purity of manufacture of regenerative 
therapies [34]. Safety is of prime concern to ensure therapies do not have a deleterious effect 
on the patient. Efficacy generally refers to the ability of a product to cause a functional 
response in the patient, and is related to the potency of the therapy. Purity of manufacture 
assessments can be used to determine the quality and capability of manufacturing processes. 
Suitable characterisation strategies will depend on the type of product being assessed. 
Appropriate tools and techniques for the assessment of devices, cell-based therapies and 
combination products are discussed below and shown in figure 6. 
 
Insert Figure 6 
 
Cell-based products involve the use of either a single cell type or a combination of cell 
types to provide a positive therapeutic response once implanted in the patient [35]. These 
cells are hypothesised to act in several ways in vivo, including: repairing the function of the 
surrounding tissue by acting as replacement cells; by secreting various growth-promoting 
agents to encourage surrounding cells to act as repair agents; and, by mobilising existing 
niche stem cell populations to migrate to the affected area to repair the site of damage. 
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(a) Safety 
 
The sterility of cell-based products also needs to be assured. For this purpose, existing 
quantification techniques for measuring safety parameters such as bacterial and fungal load, 
virus contamination and endotoxin levels appear to be sensitive enough to prevent adverse 
patient events. Contamination from culture media needs to be tested for and eliminated. In 
addition, cells are often passaged for extended amplification times, which can lead to cellular 
senescence, as well as genetic and epigenetic changes [36, 37]. Although suitable techniques 
with the necessary precision to assess these risks exist, many require long incubation times, 
for example 14 days for bacterial testing, and thus new rapid test methods are required. There 
are currently a number of methods available to monitor the interactions that occur between 
cells with their environment in vitro, including those based on the assessment of 
immunochemical and biomolecular markers. However, whereas each has its own merits, no 
one provides for the non-invasive, rapid, specific and non-destructive analysis of living cells. 
Of the techniques that might provide some of these attributes, Raman spectroscopy has 
shown promise, as evidenced by its increasing utility in the life sciences sector in recent 
years. One of the drivers for this transformation has been the evolution of the instrumentation 
to the stage where the technique’s potential can be realised in complex solutions. 
In the case of allogeneic therapies, where cells are derived from an unrelated donor, the 
autoimmune response needs to be assessed, particularly to determine if immuno-suppressants 
will be needed [38]. Another concern regarding safety measurements is the current inability 
to remove all unwanted cells [39]. For this to occur, current cell detection methods will need 
to be sensitive enough to detect as few as tens of cells in a large cell suspension. Considering 
that current advanced cell sorters claim to only have a sensitivity limit of 98% [40], there 
needs to be significant advances in this technology to ensure patient safety. However, the 
multiple purification steps required to ensure a sufficient standard of quality may add 
significant and unsustainable costs to the product, in terms of reagents, work hours and also 
initial cell numbers required to give enough purified product. 
The role of these cell based products, and in particular the evaluation of human 
mesenchymal stem cells for cell-based therapies in tissue injury and degenerative diseases, 
requires rapid accurate evaluation of cell source quality at a level that satisfies the stringent 
guidelines laid down by the regulators. DNA microarray technology can be used as a 
technique to assess relevant cellular pathways, such as senescence, as well as the recognised 
genetic changes that have been shown to occur with the extensive ex vivo expansion that is a 
prerequisite to obtain the cell numbers that are necessary for human cell-based therapy 
protocols. 
Understanding the genes that dictate the special properties of stem cells has implications 
for both stem cell biology and RM. Microarray analysis measures the global expression of 
genes and can thereby provide insight into the genetic processes expressed in stem cells. 
Microarray data from tissue-specific reference files can be compared to microarray data of 
stem cells making it possible to identify similarities in particular geno/phenotypes while also 
revealing other novel signatures. Hence, microarray analysis can be used to better understand 
stem cell differentiation and make a significant contribution to the biosafety issues of future 
cell-based therapies and RM products. 
 
(b) Efficacy 
 
Proper characterisation and understanding of cell function is the most important factor in 
determining whether a cell-based therapy will function effectively in vivo. However, as 
complete characterisation of some cell processes is still unknown, it is very difficult to 
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accurately predict every consequence of a particular cell once placed within a patient. 
Efficacy tests should always be cell-specific, and ideally test the function of the cell that will 
be required in an in vivo situation. In some cases, in vitro assays can be used as surrogate 
measures [41]. Such measures can often provide more sensitive and useful data than in vivo 
trials in an animal model [42]. Clinical endpoints have to be defined at an early stage to allow 
for proper evaluation of cell-based therapies in patient trials. For cell-based treatments, the 
end-points will have to be patient-specific, relative to the age of the patient, as well as being 
related to when the disease was diagnosed, to account for how any existing complications 
will affect the treatment outcome [3]. However, due to the complexity of several clinical 
applications, optimal efficacy measurements may evolve over time due to improved clinical 
information being available to inform the decision. Quantifying efficacy measurements is 
another challenge for product developers, but can only be focussed on once appropriate 
specific functional assays have been identified. With regards to in vitro testing, the sensitivity 
of measurements will always depend on the detection system that is being used. Therefore, 
the design of the functional assay, and identifying its key output requirements, is likely to be 
more challenging than the sensitivity of the detection system itself. 
 
(c) Purity of Manufacture 
 
Many scientists consider cell viability as the primary factor for determining the cellular 
effect of these advanced therapies once implanted in the body. This can be measured using 
various simple assays [43] as well as more sophisticated measures of cell metabolic activity 
[44] - with both providing quantitative data. However, most of these viability percentages 
simply measure how many cells are “alive”, not how many cells are actively metabolising 
and playing a productive role in their environment. In terms of these advanced therapies, 
identifying the cell phenotype, function and mode of action will be critical for specific 
clinical applications. Biomarkers may be important in distinguishing different cell 
phenotypes, but they do not always provide a correlation to cell function [45]. Therefore, in 
terms of cell-based therapies, how the cells act in the body might be more important than 
their immunophenotype in vitro. Cellular morphology can also be used to analyse cell 
populations using various microscopy techniques to determine if cells appear true to their 
phenotype [46, 47]. In all these cases, though, the safety and efficacy of the product is being 
determined essentially by implication rather than by understanding of its mode of action. 
To meet product specifications, cell number and cell viability measurements must be 
accurate so that specific product dose can be determined. However, the accuracy of cell 
counts can also be variable, from both manual and automated systems [48]. Therefore, while 
automated cell counting systems have several advantages over manual counting, 
improvements still need to be made. Of note, the final product acceptance range should be 
carefully considered as the limitations of the instrument must be taken into account. This may 
include the tolerancing of specifications, as well as factoring in measurement system errors 
that may contribute to misleading data. An extremely narrow range might cause products to 
be rejected due to these inaccuracies rather than actual product failure. 
There are many challenges associated with characterising regenerative therapies. From a 
regulatory perspective, these advanced treatments must not only be safe and effective for 
their designated indication, but must also be made by high quality manufacturing processes. 
Whilst a number of existing technologies are available to characterise regenerative therapies, 
many are time consuming, expensive and disruptive. In general, there is a need to identify 
suitable surrogate in vitro tools, define clinical endpoints early on and develop product 
specifications that can be met by current manufacturing processes. In conclusion, there is a 
need for improved stakeholder involvement in product characterisation, to allow the 
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manufacture of the best possible regenerative therapies within the shortest timeframe and at 
an economic cost. 
 
7. Conclusions 
 
This paper has described the challenges associated with the precision manufacturing of living 
stem cell therapies. In particular, it has summarised the results of work that has taken an 
automation and improvement approach to removing the process variation inherent in manual 
operations for cell number expansion and the subsequent improvement of the biological 
process to a higher precision by the application of process quality engineering techniques in 
this new domain. This approach has allowed the measurement of the current achievable 
variation in the underlying processes and assisted in the reduction of cost of goods supplied, 
critical to the uptake of these new therapeutics. With improving understanding of the 
evolutionary trajectory of processing platforms, and clearer perspectives on the measurement 
and characterisation techniques that will be applied in the coming decade, the next step is to 
take quality by design, design led, approaches earlier in the new product introduction process. 
Such approaches are challenging in this domain because of the requirement to understand and 
work around the natural variation in the living, plastic, product; the need to apply biological 
characterisation methods that are practical and demonstrable surrogates for measuring the 
way the product behaves in vivo; and because of the need to recognise and accommodate the 
regulatory constraints on manufacturing and on clinical trials. With more experience in 
manufacturing there will be increasing understanding of the variation that can be achieved 
from the manufacturing process and consequently the tolerance ranges it can deliver. The 
application of such therapies will give increased understanding of the variation allowable in 
the product while ensuring therapeutic effect. Matching what is required with what can be 
achieved and the inevitable increases in precision demanded with time will identify the 
requirements for new, more precise processing platforms. Increased understanding of the 
underlying biological processes and their interaction with approaches to manufacturing 
technology will be needed to create the step change required for the next generation of 
scalable precision production systems capable of more than replicating and incrementally 
improving the performance of the human operator. 
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Figure Captions 
 
Figure 1. This figure shows a selection of data from the automated production of key 
platform cell types with application in cell based therapies. Automation is a major step in 
achieving scalability and reducing background variability in cell based therapy production. 
Transfer from a manual to an automated process requires demonstration of product quality 
equivalence using the best available measurement methods. Typically this includes the 
growth rate of the cells. Other quality measures are more diverse. Here we show comparison 
of transcript levels to a master cell bank for 13 gene expression products (neural stem cells), 
karyotype and surface/intracellular pluripotency marker expression (embryonic stem cells), 
and typical surface marker expression and inducible alkaline phosphatase activity 
(mesenchymal stem cells). Morphology also varies between cell types and subjective visual 
assessment is considered important. 
 
Figure 2. This figure shows the outcome of a process capability measurement and 
improvement exercise using quality engineering tools for an exemplar automated human cell 
production process. The process quality output assessed was cell yield. The process 
improvement team identified that the process mean of the product from the automation was 
lower than that from the manual but had lower variability (and therefore a better potential 
process capability if centred in the specification). Cause and effect analysis was used to 
identify potential reasons for the differences in performance. An improved automated process 
was then validated to demonstrate a CpK of 0.45. This is better than could possibly be 
achieved in the manual system given the background process variation. 
 
Figure 3. Six sigma quality principles and statistical methodology have been applied to the 
quality improvement of Automated Ultra-Precision Engineered Manufacturing Processes for 
Cell Therapeutic Products. A formalized six sigma quality improvement strategy, structured 
in the following 5 phases: define, measure, analyse, improve and control (DMAIC) is shown 
here to emphasise the objectives of each phase and to illustrate the type of activities, together 
with examples of the statistical tools (shaded boxes), that were applied to reduce variation 
and defect rates for an exemplar automated human cell production process. Six sigma is a 
business management strategy originally developed by Motorola USA in 1986. 
 
Figure 4. This roadmap illustrates the application of a six sigma approach to evaluate and 
compare the behaviour of an existing manual process and a fully automated prototype process 
for the in vitro expansion of a selected anchorage-dependent cell line. Detailed process maps 
were generated for both processes to identify key sub-process steps. A cause-and-effect 
diagram and matrix was constructed to identify key process input variables (KPIV). The 
measurement system for a selected key process output variable (KPOV = Cell Yield) was 
validated (Gage R&R). Plots of individual observations (I chart) and moving ranges (MR 
chart) for variables data were generated from manual and automated culture runs to test for 
special causes and verify statistical process stability. This data was used to construct short-
term process capability (Cp, CpK) histograms for the manual and automated processes to 
identify the process improvement opportunity and provide a scientific basis for determining 
the requirement for process adjustments. Informed by the differences between the manual and 
automated processes, categorized within critical sub-processes, the improvement team 
returned to the cause-and-effect matrix to identify root causes of the effects revealed by the 
capability analysis. An improvement strategy leveraging the identified key process input 
variables was targeted at increasing process output yield and reducing process output yield 
variation to create an automated, scalable process with a Cp>1. 
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Figure 5. This figure shows a selection of data from the application of factorial designed 
experiments to an automated mesenchymal stem cell production process. This experiment 
was conducted as part of a systematic process improvement exercise. Initially the critical to 
quality attributes were defined through consultation with end users. The performance of the 
process for these key outputs was measured and the process analysed to identify key input 
parameters likely to impact on these attributes. The factors in the design, cell seeding density, 
foetal calf serum concentration, media volume and incubation time were screened for impact 
on the outputs. The data ranks the input parameters by statistical significance of effect on the 
process outputs (growth and a surface marker shown) but also shows where critical 
interdependencies exist. This is a necessary and efficient method to achieve process 
characterisation and optimisation. 
 
Figure 6. This figure shows the range of techniques that can be applied to analysing 
regenerative medicine products and how these techniques contribute to the measurement of 
safety, efficacy and purity of manufacture for medical device based products, cell based 
products and combination products that have both device and cell based product 
characteristics. The figure highlights the additional complexity associated with taking the cell 
based approach. Also it is important to recognise that a cell based product may require a 
purpose designed delivery device and consequently be regulated as a combination product. 
(Acronym definitions: PCR - polymerase chain reaction and q – quantitative PCR, GTL – gas 
to liquid, ELISA - Enzyme-linked immunosorbent assay, FRAP - Fluorescence recovery after 
photobleaching). 
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Objectives 
Define project goal, 
scope, process and 
customers (internal & 
external) 
Measure status of 
current process 
operation & quantify 
the problem 
Analyse  sources and 
potential root causes 
of process variability 
and/or defects 
Determine solution 
alternatives that 
address root causes 
Maintain 
improvement by 
monitoring the 
process 
Activities 
Define customer & 
business  requirements  
Develop detailed 
process map. Identify 
key process steps 
Identify value/non- 
value added process 
steps 
Create process model; 
Y=f(x),  to relate KPIV 
with KPOV 
Validate & Implement 
monitoring & control  
systems 
Identify and quantify 
the improvement 
opportunity 
Identify key process 
output variables 
(KPOV). Define 
specification limits 
Develop hypotheses:  
causes of variability 
(common or special 
cause) and/or defects 
Confirm which KPIV 
give the most 
leverage on the 
outputs 
Implement Statistical 
Process Control 
Establish performance 
standards for CTQs 
Define relationship 
between KPOV and 
CTQs 
Identify critical KPIV 
for potential leverage 
(vital X’s)  
Define Control Limits 
for KPIV 
Measure short term 
process capability 
(KPOVs) (KPIV) 
Define  customer 
critical-to-quality 
characteristics (CTQs) 
to be improved (defects) 
Identify key process 
input variables (KPIV) 
Analyse & identify the 
KPIV that have 
greatest impact on 
KPOV; develop Y=f(x) 
relationship 
Determine optimum 
levels for KPIV to 
achieve desired KPOV 
and CTQ 
Verify the business 
benefits (increased 
profitability/savings) 
Develop top level 
process map 
Validate 
measurement 
systems for KPOV 
 
Validate 
measurement 
systems for KPIV 
 
Create the Project 
Charter.  
Measure baseline 
stability & capability 
(KPOVs) 
 
Implement (adjust the 
process), confirm  & 
verify  improvement  
 
Toolkit 
Project Charter 
Detailed Process 
Maps 
Cause &Effect (C&E) 
Fishbone matrix 
Design of 
Experiments (DOE) 
Process Capability 
Measurement (CpK) 
Process flow diagram 
(SIPOC) 
Data Collection Plan Pareto Charts 
Risk Analysis (FMEA, 
FMECA, FTA, PHA, 
HACCP, HAZOP) 
Control Plans 
Kano Analysis Run Charts Graphical Data Analysis 
Measurement System 
Analysis (Gage R&R) 
Statistical Process 
Control Charts 
Voice of the 
Customer (VOC) 
Process Capability 
Measurement (CpK) 
Risk Analysis (FMEA, 
FMECA, FTA, PHA, HACCP, 
HAZOP) 
Robust Design Time Series Charts 
Voice of the Business 
(VOB) 
Measurement System 
Analysis (Gage R&R) 
Root Cause Analysis 
Response Surface 
Methodology (RSM) 
 
Quality Function 
Deployment (QFD) 
Cause &Effect (C&E) 
Fishbone diagrams 
Hypothesis Testing   
CTQ tree Pareto Charts 
Variance, Regression & 
Correlation Analysis 
  
Historical Data Plots  
Design of Experiments 
(DOE) 
  
                           Figure 3 
Define Measure Analyse Improve Control
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I-MR Chart: Number of cells harvested in Automated Culture
I-MR Chart: Number of cells harvested in Manual Culture
1
• 6 Key 
Process 
Steps
• 30 KPIV
KPOV
• Cell number
• Cell viability
• Cell function
• Cell safety
• Time & cost
Cause & Effect Matrix
71 KPIV
Initial Evaluation of Key Inputs & Outputs
Manual Automated
Count 56 44 32 28 56210 148 146 134 108 70 60 58
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Baseline Measurement & Process 
Capability Analysis
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Process Capability of Manual Culture System  for  Cell Yield
(using 90.0% confidence)
Process Capability of A utomated Culture System for  Cell Yield
(using 90.0% confidence)
            
  
Figure 4
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Figure 5
Technique Analysis Capability 
D
evice 
Cell-based 
Com
bination 
Safety 
Efficacy 
Purity of 
M
anufacture 
Broth & agar Bacterial growth       
PCR assay Bacterial and viral presence       
Blood pathology testing Donor contamination of biologics       
In vitro culture Cytotoxicity, endotoxin       
GTL banding of 
metaphase spreads 
Karyotyping       
Fluorescence in situ 
hybridisation 
Karyotyping       
Flow cytometry 
Cell number, viability and 
phenotyping 
      
Animal models 
Toxicology, immune response, cell 
effectiveness 
      
ELISA Cell effectiveness       
Trypan blue assay Cell number and viability       
Metabolic assay Cell viability       
Optical microscopy 
(including fluorescence) 
Morphology, structure and function       
Histology 
Morphology, structure and 
composition 
      
Diffusion cell Diffusion of nutrients and waste       
FRAP Diffusion of nutrients and waste       
NMR techniques 
Spectroscopy: composition; 
Imaging: structure and diffusion 
      
Compression testing Mechanical properties       
Optical spectroscopy 
(Including Raman) 
Composition, Cell Viablity       
DNA Microarray 
Technology - qPCR 
Gene expression, SNP analysis       
 
 
Figure 6 
 
 
 
 
 
